Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
LIPID DISORDERS / LETTER TO THE EDITOR
Lipoprotein (a) measurement: potential for personalized cardiovascular disease management in a patient with acute myocardial infarction
1
1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
2
Center for Endocrinology, Diabetes and Preventive Medicine, University of Cologne, Faculty of Medicine and University Hospital, Cologne, Germany
3
Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Lodz, Poland
Submission date: 2024-04-29
Final revision date: 2024-04-30
Acceptance date: 2024-05-03
Online publication date: 2024-05-03
Corresponding author
Jakub Michal Zimodro
Jakub Michal Zimodro 1st Chair and Department of Cardiology Medical University of Warsaw, Poland
Jakub Michal Zimodro 1st Chair and Department of Cardiology Medical University of Warsaw, Poland
Arch Med Sci 2024;20(3):1043-1047
TOPICS
REFERENCES (17)
1.
Björnson E, Adiels M, Taskinen MR, et al. Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis. J Am Coll Cardiol 2024; 83: 385-95.
2.
Kronenberg F. Lipoprotein(a): from causality to treatment. Curr Atheroscler Rep 2024; 26: 75-82.
3.
Kaiser Y, van der Toorn JE, Singh SS, et al. Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification. Eur Heart J 2022; 43: 3960-7.
4.
Sosnowska B, Stepinska J, Mitkowski P, et al. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels. Arch Med Sci 2024; 20: 8-27.
5.
Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022; 43: 3925-46.
6.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-88.
7.
Patel AP, Wang M, Pirruccello JP, et al. Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. Arterioscler Thromb Vasc Biol 2021; 41: 465-74.
8.
Gaba P, O’Donoghue M, Lopez JA, et al. Abstract 12103: Intraindividual Variability in Serial Lipoprotein(a) Concentration Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial. Circulation 2023; 148: A12103.
9.
Kronenberg F, Mora S, Stroes ESG, et al. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis 2023; 374: 107-20.
10.
Awad K, Mikhailidis DP, Katsiki N, Muntner P, Banach M. Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group. Effect of ezetimibe monotherapy on plasma lipoprotein(a) concentrations in patients with primary hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials. Drugs 2018; 78: 453-62.
11.
Jang JY, Kim S, Cho J, Chun SY, You SC, Kim JS. Comparative effectiveness of moderate-intensity statin with ezetimibe therapy versus high-intensity statin monotherapy in patients with acute coronary syndrome: a nationwide cohort study. Sci Rep 2024; 14: 838.
12.
Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomized, open-label, non-inferiority trial. Lancet 2022; 400: 380-90.
13.
Banach M, Reiner Z, Cicero AFG, et al. 2022: the year in cardiovascular disease – the year of upfront lipid lowering combination therapy. Arch Med Sci 2022; 18: 1429-34.
14.
Katsiki N, Vrablik M, Banach M, Gouni-Berthold I. Inclisiran, low-density lipoprotein cholesterol and lipoprotein (a). Pharmaceuticals (Basel) 2023; 16: 577.
15.
Zhang Y, Chen H, Hong L, et al. Inclisiran: a new generation of lipid-lowering siRNA therapeutic. Front Pharmacol 2023; 14: 1260921.
16.
O’Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med 2022; 387: 1855-64.
17.
Thau H, Neuber S, Emmert MY, Nazari-Shafti TZ. Targeting lipoprotein(a): can RNA therapeutics provide the next step in the prevention of cardiovascular disease? Cardiol Ther 2024; 13: 39-67.
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
